{"url_path":"/sec/clov/8-k/2026-06-12/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-12","source_url":"https://www.sec.gov/Archives/edgar/data/1801170/0001801170-26-000148-index.html","accession_number":"0001801170-26-000148","cik":"0001801170","ticker":"CLOV","issuer_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE","edgar_url":"https://www.sec.gov/Archives/edgar/data/1801170/0001801170-26-000148-index.html","primary_entity_key":"0001801170","primary_entity_name":"CLOVER HEALTH INVESTMENTS, CORP. /DE"},"word_count":396,"has_tables":true,"body_markdown":"Item 5.07. Submission of Matters to a Vote of Security Holders.\n\nOn June 10, 2026, Clover Health Investments, Corp. (the \"Company\") held its 2026 Annual Meeting of Stockholders (the \"Annual Meeting\") virtually via live webcast. At the Annual Meeting, the Company’s stockholders voted on three proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 28, 2026. Holders of the Company’s Class A common stock were entitled to one vote for each share held as of the close of business on April 15, 2026 (the “Record Date”) and holders of the Company’s Class B common stock were entitled to ten votes for each share held as of the close of business on the Record Date. The Class A common stock and Class B common stock voted as a single class on all matters. The matters voted upon at the Annual Meeting and the final voting results, as certified by the Company's independent inspector of election, are set forth below.\n\nProposal 1: Election of Three Class II Directors.\n\nDemetrios L. Kouzoukas, Andrew Toy and Thomas L. Tran were each elected to the Company’s Board of Directors as Class II directors, to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified. The results of the election were as follows:\n\nFORWITHHELDBROKER NON-VOTE\n\nDemetrios L. Kouzoukas1,003,131,25111,409,888177,790,033\n\nAndrew Toy1,011,117,8143,423,325177,790,033\n\nThomas L. Tran996,918,87917,622,260177,790,033\n\nProposal 2: Non-binding advisory vote to approve the compensation of the Company's Named Executive Officers for 2025.\n\nThe stockholders vote to approve, on a non-binding advisory basis, the compensation of the Company's Named Executive Officers for 2025. The results of the vote were as follows:\n\nFORAGAINSTABSTAINBROKER NON-VOTE\n\n1,003,065,4029,811,8251,663,812177,790,033\n\nProposal 3: Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.\n\nThe stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the vote were as follows:\n\nFORAGAINSTABSTAIN\n\n1,188,467,6632,471,6061,391,903\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nClover Health Investments, Corp.\n\nDate:June 12, 2026By:/s/Karen M. Soares\n\nName:Karen M. Soares\n\nTitle:General Counsel and Corporate Secretary"}